共 41 条
[1]
Sun CI(2014)Regulatory status of Drug Master File in Taiwan 2009–2011 J Gener Med 11 56-63
[2]
Lu FC(2020)DMF filing procedure in US, Europe and Canada: a review Int J Drug Reg Aff 8 7-14
[3]
Lu KJ(2013)Comparison of drug approval process in USA and Europe J Pharm Sci 5 131-136
[4]
Liao TY(2010)FDA perspectives: Common deficiencies in abbreviated new drug applications: Part 1: drug substance Pharm Tech 31 50-59
[5]
Gau CS(2010)Certification of suitability to Monographs of the European Pharmacopoeia: top ten deficiencies, (beginning of 2011) Strasbourg, PA/PH/CEP 10 1-5
[6]
Chakraborty K(2009)Where is industry getting it wrong? A review of quality concerns raised at day 120 by the Committee for Medicinal Products for Human Use during European Centralised Marketing Authorisation Submissions for chemical entity medicinal products J Pharm Pharm Sci 12 181-198
[7]
Kashyap UN(2012)Deficiencies in generic product dossiers as submitted to the WHO Prequalification of Medicines Programme J Gener Med 9 63-64
[8]
Gupta V(2014)Review of quality deficiencies found in active phamaceutical ingredient master files submitted to the who Prequalification of Medicines Programme J Pharm Pharm Sci 17 169-186
[9]
Raghunandan HV(2010)Sample size calculation Int J Ayuverda Res 1 55-57
[10]
Srinivasan A(2020)Evaluating the success of ZaZiBoNa, the Southern African development community collaborative medicines registration initiative Ther Innov Regul Sci 54 1319-1329